Ameriprise’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-34,900
Closed -$79.6K 4044
2024
Q2
$79.6K Sell
34,900
-600
-2% -$2.29K ﹤0.01% 3791
2024
Q1
$153K Hold
35,500
﹤0.01% 3724
2023
Q4
$108K Sell
35,500
-2,550
-7% -$4.79K ﹤0.01% 3806
2023
Q3
$54.8K Sell
38,050
-89,334
-70% -$173K ﹤0.01% 3833
2023
Q2
$317K Sell
127,384
-22,421
-15% -$61.3K ﹤0.01% 3594
2023
Q1
$401K Buy
149,805
+33,395
+29% +$160K ﹤0.01% 3505
2022
Q4
$632K Sell
116,410
-1,179
-1% -$9.88K ﹤0.01% 3315
2022
Q3
$1.47M Buy
117,589
+4,866
+4% +$55.6K ﹤0.01% 2929
2022
Q2
$557K Buy
112,723
+4,422
+4% +$24.5K ﹤0.01% 3360
2022
Q1
$823K Buy
108,301
+7,850
+8% +$74.4K ﹤0.01% 3290
2021
Q4
$1.02M Sell
100,451
-21,996
-18% -$280K ﹤0.01% 3242
2021
Q3
$1.64M Buy
122,447
+6,796
+6% +$111K ﹤0.01% 2948
2021
Q2
$2.54M Buy
115,651
+42,288
+58% +$939K ﹤0.01% 2829
2021
Q1
$1.76M Sell
73,363
-16,336
-18% -$380K ﹤0.01% 2904
2020
Q4
$1.61M Buy
89,699
+17,694
+25% +$264K ﹤0.01% 2886
2020
Q3
$832K Sell
72,005
-6,952
-9% -$115K ﹤0.01% 3048
2020
Q2
$1.92M Sell
78,957
-9,564
-11% -$158K ﹤0.01% 2625
2020
Q1
$976K Buy
88,521
+9,110
+11% +$170K ﹤0.01% 2835
2019
Q4
$2.1M Buy
79,411
+11,312
+17% +$265K ﹤0.01% 2712
2019
Q3
$1.55M Sell
68,099
-8,863
-12% -$279K ﹤0.01% 2818
2019
Q2
$2.36M Buy
76,962
+15,562
+25% +$328K ﹤0.01% 2649
2019
Q1
$1.02M Buy
61,400
+27,278
+80% +$517K ﹤0.01% 3034
2018
Q4
$654K Buy
+34,122
New +$1.28M ﹤0.01% 3102
2018
Q2
Sell
-30,769
Closed -$1.14M 3714
2018
Q1
$1.14M Buy
+30,769
New +$821K ﹤0.01% 2922

Ameriprise's GTHX Position: Q3 2024 in Review

Ameriprise sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 34,900 shares — an estimated $79.6K sold.

Ameriprise first reported a position in GTHX in Q1 2018 and held it in 24 quarters. The position peaked at $2.54M in Q2 2021. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.

  • Ameriprise reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Ameriprise sold 34,900 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $79.6K.
  • Ameriprise first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2018 and held it in 24 quarters.
  • Ameriprise's G1 Therapeutics, Inc. Common Stock position peaked at $2.54M in Q2 2021.
  • 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Ameriprise's 13F filing for Q3 2024, filed 14 Nov 2024.